Analysts Set Expectations for SCYNEXIS FY2029 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Brookline Capital Management issued their FY2029 EPS estimates for shares of SCYNEXIS in a note issued to investors on Thursday, March 13th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of $0.39 for the year.

Separately, StockNews.com downgraded shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th.

SCYNEXIS Price Performance

NASDAQ:SCYX opened at $1.05 on Monday. The firm’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $1.24. SCYNEXIS has a one year low of $0.82 and a one year high of $3.07. The company has a market cap of $40.93 million, a PE ratio of -1.42 and a beta of 1.67.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, March 12th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The business had revenue of $0.98 million for the quarter.

Institutional Investors Weigh In On SCYNEXIS

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in SCYNEXIS by 10.0% during the 3rd quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock worth $594,000 after purchasing an additional 36,405 shares during the last quarter. AMH Equity Ltd raised its holdings in SCYNEXIS by 4.3% during the 4th quarter. AMH Equity Ltd now owns 626,052 shares of the company’s stock worth $758,000 after purchasing an additional 26,052 shares during the last quarter. XTX Topco Ltd bought a new position in SCYNEXIS during the 3rd quarter worth approximately $25,000. Millennium Management LLC bought a new position in SCYNEXIS during the 4th quarter worth approximately $31,000. Finally, Squarepoint Ops LLC bought a new position in SCYNEXIS during the 4th quarter worth approximately $53,000. 54.37% of the stock is currently owned by institutional investors and hedge funds.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.